RESUMO
The incorporation of personalized medicine interventions into routine healthcare constitutes an opportunity to improve patients' quality of life, as it empowers implementation of innovative, individualized clinical interventions that maximize efficacy and/or minimize the risk of adverse drug reactions. In order to ensure equal access to genomic testing for all patients, the costs associated with these interventions must be reimbursed by payers and insurance bodies. As such, it is of utmost importance to thoroughly evaluate these interventions both in terms of their clinical effectiveness and their economic cost. This article discusses the impact of personalized medicine interventions in terms of both health outcomes and value, which directly impacts on their pricing and reimbursement by the various national healthcare systems.
Assuntos
Reembolso de Seguro de Saúde/economia , Avaliação de Resultados em Cuidados de Saúde/economia , Assistência ao Paciente/economia , Farmacogenética/economia , Medicina de Precisão/economia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/economia , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos/genética , Política de Saúde/economia , Política de Saúde/tendências , Humanos , Reembolso de Seguro de Saúde/tendências , Avaliação de Resultados em Cuidados de Saúde/tendências , Assistência ao Paciente/tendências , Farmacogenética/tendências , Medicina de Precisão/tendênciasRESUMO
This article describes how methods of personalized medicine-specifically, pharmacogenetic (PGx) testing-can benefit private health plans, benefits managers, care providers and consumers alike. The authors cover pharmacogenomics as a science and also introduce an innovative way to optimize drug treatments. The article touches on some important clinical outcomes drawn from a recent study in community pharmacy and reviews the application and return on investment of PGx testing in disability and medication management.